No Data
No Data
Chordia Therapeutics - The international non-proprietary name for pharmaceutical CTX-712 has been determined.
Chordia Therapeutics announced on the 20th that the World Health Organization (WHO) has publicly released the International Nonproprietary Name (INN) for their developed CLK inhibitor drug CTX-712 as the recommended INN (rINN). In the future, this developmental product will be described as "rogocekib" instead of the development code CTX-712. INN is the globally accepted specific name for pharmaceutical products.
Chordia, etc., [stocks with attractive tastes from changes in volume].
Closing price, previous day comparison, volume: <6185> SMN 352,793,344,900 <7831> Wilco HD 135,184,398,400 <2588> P Water 30,802,121,03300 <3079> DV x 922,421,15200 <190A> Chordia 222,214,033,300 <4288> Azugent 566,567,1100 <3932> Akatsuki 24,382,282,16400 <3647> G3 HD 11,643,614,00
Chordia Therapeutics Advances Cancer Drug Development
Volume change rate ranking (10 AM slot) - Geocode, KADOKAWA, etc. are ranked.
*In the volume change rate ranking, you can understand the interest of market participants such as trends in searches by comparing the average volume of the last 5 days with the volume on the distribution day. *Volume change rate top [As of 10:32 on November 20](Comparison of average volume of the last 5 days) Stock Code Stock Name Volume 5-day average volume Volume change rate Stock price change rate <7357>Geocode 158,000 30 10.84% 2.12% <9468>
Chordia Research Memo (7): In the August 2024 period, there was no recognition of business revenue, resulting in an operating loss being recognized.
■ The performance trend of Chordia Therapeutics <190A> 1. Overview of performance for the fiscal year ending August 2024 There were no recorded business revenues for the fiscal year ending August 2024 (previous period reported milestone revenue of 2500 million yen), resulting in an operating loss of 1801 million yen (compared to a profit of 212 million yen in the previous period), an ordinary loss of 1824 million yen (compared to a profit of 225 million yen), and a net loss for the period of 1827 million yen (compared to a profit of 223 million yen). Research and development expenses totaled 1499 million yen, an increase of 497 million yen compared to the previous period.
Chordia Research Memo (6): MALT1 inhibitors have been licensed out to Ono Pharmaceutical for a maximum condition of over 50 billion yen.
■Chordia Therapeutics <190A> development pipeline 2. MALT1 inhibitors (1) Mechanism of action of MALT1 inhibitors and background of early development. MALT1 inhibitors are a development pipeline expected to show therapeutic effects for refractory lymphoma, achieving early development to OncoOne in 2020 after conducting preclinical trials. In refractory lymphoma, factors in T cell signaling or B cell signaling pathways (T cell receptor CD28, B cell receptor
No Data
No Data